Results 71 to 80 of about 86,629 (276)

Chalazia development in multiple myeloma: a new complication associated with bortezomib therapy

Hematology Reports, 2015
Multiple myeloma (MM) is a neoplasm of plasma cells within the bone marrow. A major impact on improving survival in MM has been the use of the boronic acid-derived proteasome inhibitor bortezomib, a first-in-class selective inhibitor of the 26S ...
Charles Yun, Nikhil Mukhi, Valerie Kremer, Roman Shinder, Vaibhav Verma, Olcay Batuman   +5 more
doaj   +1 more source

The protective effects of the proteasome inhibitor bortezomib (velcade) on ischemia-reperfusion injury in the rat retina. [PDF]

PLoS ONE, 2013
PURPOSE: To evaluate the protective effects of bortezomib (Velcade) on ischemia-reperfusion (IR) injury in the rat retina. METHODS: The rats were randomized to receive treatment with saline, low-dose bortezomib (0.05 mg/kg), or high-dose bortezomib (0.2 ...
Fang-Ting Chen, Chung-May Yang, Chang-Hao Yang   +2 more
doaj   +1 more source

Cell‐Free DNA‐Based Theranostics for Inflammatory Disorders

Advanced Science, EarlyView.
Summary on the dual potential of cfDNA as biomarkers and therapeutic targets for inflammatory disorders. Figure was created with BioRender.com. ABSTRACT Inflammatory disorders are characterized by immune‐mediated inflammatory cascades that can affect multiple organs.
Jiatong Li, Yumei Wang, Xiaoxi Fan, Miao Xu, Jiawen Li, Wenfei Tan, Jianxiang Zhang, Heran Li   +7 more
wiley   +1 more source

Multi-omics analysis identifies repurposing bortezomib in the treatment of kidney-, nervous system-, and hematological cancers

Scientific Reports
Repurposing of FDA-approved drugs is a quick and cost-effective alternative to de novo drug development. Here, we identify genes involved in bortezomib sensitivity, predict cancer types that may benefit from treatment with bortezomib, and evaluate the ...
Peter Larsson, Maxim Olsson, Sithumini Sarathchandra, Anna Fäldt Beding, Eva Forssell-Aronsson, Anikó Kovács, Per Karlsson, Khalil Helou, Toshima Z. Parris   +8 more
doaj   +1 more source

Higher proteotoxic stress rather than mitochondrial damage is involved in higher neurotoxicity of bortezomib compared to carfilzomib

Redox Biology, 2020
Proteasome inhibitors have great success for their therapeutic potential against hematologic malignancies. First generation proteasome inhibitor bortezomib induced peripheral neuropathy is considered as a limiting factor in chemotherapy and its second ...
Ayse Tarbin Jannuzzi, Sema Arslan, Ayse Mine Yilmaz, Gulce Sari, Hande Beklen, Lucía Méndez, Maria Fedorova, Kazim Yalcin Arga, Betul Karademir Yilmaz, Buket Alpertunga   +9 more
doaj   +1 more source

Aplidin (plitidepsin) is a novel anti-myeloma agent with potent anti-resorptive activity mediated by direct effects on osteoclasts [PDF]

, 2019
Despite recent progress in its treatment, Multiple Myeloma (MM) remains incurable and its associated bone disease persists even after complete remission.
Atkinson, Emily G., Bellido, Teresita, Delgado-Calle, Jesus, Galmarini, Carlos Maria, Kurihara, Noriyoshi, Miyagawa, Kazuaki, Nelson, Jessica, Roodman, G. David   +7 more
core   +1 more source

NADH‐Reductive Stress Induced by Dihydrolipoamide Dehydrogenase Activation Contributes to Cuproptosis

Advanced Science, EarlyView.
This study demonstrates a cuproptosis mechanism involving nicotinamide adenine dinucleotide (NADH)‐reductive stress in neural cells. Copper activates dihydrolipoamide dehydrogenase under mitochondrial pH, accumulating NADH. Copper also induces mitochondrial permeability transition pore opening, facilitating NADH translocation to the cytosol and ...
Si‐Yi Zhang, Xing‐Hua Ren, Cheng‐Hong Zhang, Zhan‐You Wang   +3 more
wiley   +1 more source

Exploring the Vasculitis‐Tumors Link: Epidemiological Patterns, Mechanistic Insights, and Clinical Implications

Advanced Science, EarlyView.
This review outlines association between vasculitis and malignancies and provides practical value for clinicians in distinguishing primary vasculitis from malignancy‐associated forms and optimizing patient surveillance, improving recognition of tumor‐associated vasculitis to reduce the risk of misdiagnosis, supporting more accurate clinical decision ...
Xiaofei Shi, Zhijiao Li, Xin Ma, Bei Zhang, Xinfeng Wu, Hua Fan, Rongzeng Liu, Hongwei Jiang, Cong‐Qiu Chu   +8 more
wiley   +1 more source

Trypanocidal activity of the proteasome inhibitor and anti-cancer drug bortezomib

Parasites & Vectors, 2009
The proteasome inhibitor and anti-cancer drug bortezomib was tested for in vitro activity against bloodstream forms of Trypanosoma brucei. The concentrations of bortezomib required to reduce the growth rate by 50% and to kill all trypanosomes were 3.3 nM
Wang Xia, Steverding Dietmar
doaj   +1 more source

Blastic plasmacytoid dendritic cell neoplasm: Genomics mark epigenetic dysregulation as a primary therapeutic target [PDF]

, 2019
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy for which there is still no effective B therapy.
Abate F., Agostinelli C., Amente S., Berti E., Bertolini F., Brundu F., Cerroni L., Dellino G. I., Etebari M., Facchetti F., Falini B., Fuligni F., Indio V., Laginestra M. A., Melle F., Motta G., Orecchioni S., Paulli M., Piccioni R., Pileri A., Pileri S. A., Pimpinelli N., Rabadan R., Rossi M., Sabattini E., Sapienza M. R., Tabanelli V., Talarico G., Tarantino G., Tripodo C., Truni M.   +30 more
core   +2 more sources